NASDAQ
05.06.26 | 21:59
23,140 US-Dollar
-6,22 % -1,535
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Arcus Biosciences In Clinical Trial Collaboration With Bristol Myers Squibb For Renal Cell Carcinoma | 282 | AFX News | NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY).Under... ► Artikel lesen | |
| 18.05. | Truist assumes Arcus Biosciences stock with buy on RCC potential | 2 | Investing.com | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 11.05. | Arcus Biosciences verfehlt Prognosen für Q1 2026 - Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 05.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.04. | What's Going On With Arcus Biosciences Stock On Wednesday? | 4 | Benzinga.com | ||
| 22.04. | Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? | 1 | Zacks | ||
| 21.04. | Arcus Biosciences: BofA bestätigt "Neutral"-Rating nach Studiendaten von Konkurrent Merck | 6 | Investing.com Deutsch | ||
| 21.04. | Arcus Biosciences stock rating held at Neutral by BofA on rival trial data | 2 | Investing.com | ||
| 20.04. | Leerink senkt Kursziel für Arcus Biosciences nach Ende der Gilead-Kooperation | 19 | Investing.com Deutsch | ||
| 20.04. | Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end | 2 | Investing.com | ||
| 20.04. | Mizuho reiterates Arcus Biosciences stock rating after trial halt | 3 | Investing.com | ||
| 20.04. | Arcus Biosciences: Aktie bricht nach Stopp von Lungenkrebsstudie ein | 2 | Investing.com Deutsch | ||
| 20.04. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.03. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | Arcus Biosciences: Gewinn pro Aktie übertrifft Erwartungen, Umsatz verfehlt Prognose im 4. Quartal 2025 | - | Investing.com Deutsch | ||
| 25.02. | Arcus Biosciences GAAP EPS of -$0.89 beats by $0.14, revenue of $33M beats by $8.06M | 1 | Seeking Alpha | ||
| 25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.02. | Arcus Biosciences Earnings Review: Q4 Summary | 2 | Benzinga.com | ||
| 25.02. | Arcus Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -4,44 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,57 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | -9,80 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | -12,76 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| MINERALYS THERAPEUTICS | 23,720 | -5,31 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | -7,02 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +16,43 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,535 (-6,22 %) liegt der Kurs bei 23,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.